Is Moderna stock a hold?

An analyst downgrade put one of the year's top-performing stocks under pressure.

| More on:

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Doctors and medical specialists look at the results of a drug trial, as the race for a coronavirus vaccine continues

Image source: getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

A recent downgrade from buy to hold from a Wall Street analyst has Moderna (NASDAQ: MRNA) stock under pressure. Needham analyst Alan Carr has removed his $110 price target on the stock, citing valuation concerns.

Moderna's market cap has swelled 885% this year to around $67 billion at recent prices. Despite coming under pressure recently, this is still one of the best performing large-cap healthcare stocks of 2020.

Following a meeting on 17 December with the Food and Drug Administration's independent advisory committee, Moderna's coronavirus vaccine candidate MRNA-1273 will probably become the second vaccine to earn an Emergency Use Authorisation to prevent COVID-19.

Today, the same advisory committee will weigh in on results submitted from Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) regarding their COVID-19 vaccine candidate BNT162b2.

By the end of 2020, Moderna thinks it can deliver enough doses of mRNA-1273 for 10 million Americans, and perhaps produce enough for 500 million people in 2021. That could lead to enormous sales next year, but they probably won't last.

Commercial-stage biotechnology companies generally trade at mid-single-digit multiples of total revenue when that revenue is expected to continue growing at a healthy pace. While Moderna could record a huge windfall in 2021, it isn't likely to last. The next vaccine rolling through Moderna's pipeline probably won't have a chance to launch until 2024.

Forget about holding Moderna. It's time to think about selling your shares. If all goes well with BNT162b2 and at least a few more names on a huge list of coronavirus vaccine candidates, Moderna won't need to manufacture anything at scale by the end of 2022. Without any means to support its enormous valuation, it's hard to see how the stock can rise over the long run. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Happy man working on his laptop.
International Stock News

Prediction: This artificial intelligence (AI) stock will be the biggest winner of 2025

Artificial intelligence will be one of the biggest growth opportunities this century.

Read more »

Legendary share market investing expert and owner of Berkshire Hathaway Warren Buffett
International Stock News

Could Warren Buffett's last move as Berkshire Hathaway CEO be buying this beaten-down "Magnificent Seven" stock?

Buffett is a value investor at his core, and he doesn't often buy shares of expensive companies.

Read more »

A woman holds a soldering tool as she sits in front of a computer screen while working on the manufacturing of technology equipment in a laboratory environment.
International Stock News

Prediction: This artificial intelligence (AI) stock will be worth $5 trillion in 3 years

Let's take a closer look at the catalysts that could propel this stock toward that valuation.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

This Artificial Intelligence (AI) chipmaker just got a game-changing boost from Amazon, and Nvidia investors should be paying close attention

Amazon just made a notable investment in Nvidia's top rival.

Read more »

Happy man working on his laptop.
International Stock News

A once-in-a-decade opportunity: Here's why I'm buying Alphabet stock like there's no tomorrow

Alphabet's stock rarely gets this cheap, and right now could be a once-in-a-decade opportunity to scoop up shares at a…

Read more »

A woman looks questioning as she puts a coin into a piggy bank.
International Stock News

Is Warren Buffett's Berkshire Hathaway the smartest investment you can make today?

So, with all the uncertainty, is Berkshire Hathaway the smartest investment you can make today?

Read more »

Warren Buffet
International Stock News

7 ways Warren Buffett changed my investing approach

I'm a big fan of Warren Buffett, and have been for many years.

Read more »

iPhone with the logo and the word Google spelt multiple times in the background.
International Stock News

Down 12% this year, should you buy Alphabet stock?

The Google owner is underperforming the Nasdaq Composite, which has rallied in recent weeks.

Read more »